COMPANY
Candel Therapeutics, Inc.
At Candel Therapeutics, we are developing viral immunotherapies that are designed to cause in-situ immunization against the antigens and neoantigens presented when tumor cells lyse and stimulate activation of both innate and adaptive immune mechanisms. Currently, Candel is evaluating the effects of treatment with aglatimagene in patients with non-small cell lung cancer and localized, non-metastatic prostate cancer. From company website Source · Oct 13, 2026
Timeline
- Trial start Phase 3: Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) source ↗
- Raise Follow-on offering: $100M (total, as published), announced Feb 19, 2026. Source: SEC filing. source ↗
- Trial start Phase 2: A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec source ↗
- Debt Debt: $130M (not counted as a raise), announced Oct 14, 2025. Source: SEC filing. source ↗
- Raise Follow-on offering — Registered direct: $15M (total, as published), announced Jun 24, 2025. Source: SEC filing. source ↗
- Raise Follow-on offering: $92M (total, as published), announced Dec 16, 2024. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 2: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC source ↗
- Trial start Phase 1: GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas source ↗
- Trial start Phase 1: Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer source ↗
- Trial start Phase 2: Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) source ↗
- Trial start Phase 2: Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma source ↗
- Trial start Phase 1: Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion source ↗
- Trial start 3: Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer source ↗
- Trial start I: A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors source ↗
- Trial start Phase 1: AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) source ↗
- Trial start 2: Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma source ↗
- Trial start 1: Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas source ↗
Upcoming milestones
- 2027-02 (ESTIMATED) · Phase 2 · A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec · NCT07332000
- Oct 22, 2031 (ESTIMATED) · Phase 3 · Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) · NCT07660094
Funding
- Follow-on offering: $100M (total, as published), announced Feb 19, 2026. Source: SEC filing. source ↗
- Follow-on offering — Registered direct: $15M (total, as published), announced Jun 24, 2025. Source: SEC filing. source ↗
- Follow-on offering: $92M (total, as published), announced Dec 16, 2024. Source: company release on GlobeNewswire. source ↗
- Debt: $130M (not counted as a raise), announced Oct 14, 2025. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 13
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT01436968 | Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer | 3 | Active, not recruiting | 2011-09 | 2024-08 (actual) |
| NCT02768363 | Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | Phase 2 | Active, not recruiting | 2016-05 | 2024-11 (actual) |
| NCT07332000 | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | Phase 2 | Recruiting | Oct 30, 2025 | 2027-02 (estimated) |
| NCT07660094 | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) | Phase 3 | Recruiting | Jun 15, 2026 | Oct 22, 2031 (estimated) |
| NCT04495153 | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | Phase 2 | Active, not recruiting | Oct 13, 2020 | Dec 31, 2024 (actual) |
| NCT03131037 | Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer | Phase 1 | Completed | May 4, 2017 | Dec 1, 2021 (actual) |
| NCT03576612 | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas | Phase 1 | Completed | Feb 27, 2018 | Jun 30, 2023 (actual) |
| NCT00589875 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | 2 | Completed | 2007-03 | 2015-12 (actual) |
| NCT02446093 | Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Unknown status (ClinicalTrials.gov) | 2015-10 | 2025-12 (estimated) |
| NCT00634231 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | I | Completed | 2010-10 | 2015-12 (actual) |
| NCT00751270 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | 1 | Completed | 2005-11 | 2010-01 (actual) |
| NCT01997190 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion | Phase 1 | Completed | 2013-10 | 2015-12 (actual) |
| NCT00638612 | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) | Phase 1 | Completed | 2008-08 | 2013-05 (actual) |